The Promise and Challenges of Personalized Medicine in Hematologic Malignancies
Journal Title: Journal of Hematology & Thrombosis - Year 2015, Vol 1, Issue 2
Abstract
Personalized medicine is a rapidly emerging medical model that proposes individually customized healthcare to potentially increase the quality of clinical care and reduce health care costs. The key to the success of personalized medicine is development of diagnostics and therapeutics based upon molecular, genetic, epigenetic, pharmacogenomic and metabolic features of individual patients. Personalized medicine in oncology seeks to individualize cancer care and treatment decisions based upon features unique to each patient and each patient’s tumor. Medical decisions are then being tailored to the individual patient with the hope of providing improved quality-of-life and overall survival. Diagnostic testing is employed to select appropriate and optimal therapies based upon the context of each patient’s genetic content or other molecular or cellular tests. The concept of personalized medicine hopes to not only enhance the patient quality of life and survival but also to lower overall healthcare costs through early-detection, prevention, accurate risk assessments and more efficient health care delivery systems. However, personalized approaches in oncology face major, complex scientific and economic problems. Here, we discuss certain scientific and economic challenges that face the future of personalized medicine in the treatment of hematologic malignancies.
Authors and Affiliations
James J Driscoll
Keywords
Related Articles
- EP ID EP246516
- DOI 10.13188/2380-6842.1000007
- Views 161
- Downloads 0
The Promise and Challenges of Personalized Medicine in Hematologic Malignancies
Personalized medicine is a rapidly emerging medical model that proposes individually customized healthcare to potentially increase the quality of clinical care and reduce health care costs. The key to the success of pers...
Accidental and Surreptitious Intake of Oral Anticoagulants Including Older and Newer Agents - A Diagnostic Dilemma
The newer oral anticoagulants including dabigatran, rivaraxoban, apixaban and edoxaban are replacing warfarin in the management of atrial fibrillation and venous thromboembolism. Accidental and surreptitious overdose of...
Differences in Circulating Endothelial Progenitor Cells among Childhood Cancer Survivors Treated with and without Radiation
Radiation during childhood cancer treatment increases the propensity to atherosclerotic cardiovascular disease among adult survivors of childhood cancer. This is thought to be mediated through the damage to the underlyin...
A Case of a Successful Gestation in a Patient with an Unclassified Transfusion Dependent Congenital Dyserythropoietic Anemia and Hemoglobinopathy
Congenital Dyserythropoietic Anemias are rare congenital disorders of in effective erythropoiesis, are rarely fatal in early childhood. With the advent of safe blood transfusions and iron chelation, individuals with CDA...
Hypoplasia of Infrarenal Inferior Vena Cava: An Infrequent Cause of Repetitive Deep Vein Thrombosis and its Effects
Congenital anomalies such as the defects of inferior vena cava (IVC) are not common, however these alterations obtained from a poor embryo development benefit venous stasis which, inconsequence, will trigger a deep vein...